Head-to-head evidence
elecoglipron vs exendin-4 Fc fusion (JY09)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
elecoglipron
Developed by AstraZeneca
NCT06579105 · Phase 2 · completed
Participants receiving AZD5004 or placebo were randomized and kept blinded to treatment; a semaglutide comparator arm was open-label but was not part of the primary comparison. The highest dose produced a substantially larger drop in HbA1c than placebo, meeting the trial's main goal.
Next expected readout: May 2028 · NCT07664553 (registry estimate)
exendin-4 Fc fusion (JY09)
Developed by Beijing Dongfang Biotech
NCT06247748 · Phase 1 · completed
Every participant received the same open-label treatment with no control group, and the study measured drug-interaction and pharmacokinetic markers rather than a clinical benefit. No results have been posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: elecoglipron's landscape · exendin-4 Fc fusion (JY09)'s landscape